About the partners

Malaria Consortium is the world's leading not-for-profit organisation dedicated to the control of malaria and applies its depth of technical expertise and practical experience to develop smarter solutions that improve and save lives. Through innovation, Malaria Consortium increases the impact of malaria and disease control programmes so that they benefit all communities, including delivery in the most challenging environments. Malaria Consortium has pioneered best practices and approaches, setting the standards that others now follow. Malaria Consortium is headquartered in London, United Kingdom, with over 90% of its staff based in malaria-endemic countries supporting Ministries of Health and partners in over twenty countries. For more information, please visit www.malariaconsortium.org.

An industry leader in almost every aspect of the energy and petrochemicals business, ExxonMobil operates facilities or markets products in most of the world's countries.

We engage in a range of philanthropic activities that advance education, health and science in the communities where we have significant operations.

In 2000, we established our Africa Health Initiative in support of the Abuja Declaration on Roll Back Malaria in Africa and its goal to halve malaria deaths by 2010. Since then, we have developed on-the-ground public-private partnerships to fight malaria at the community level, progress treatment and vaccine research, and raise awareness and international support.

Today, we have the most comprehensive malaria control programme of any oil and gas major in Africa, and are the largest non-pharmaceutical corporate donor to malaria research. As well as supporting new drug development, we are helping to distribute insecticide-treated bed nets to places where they are desperately needed.

To mark World Malaria Day, we announced an additional $1 million donation, bringing our commitment to organisations engaged in important community and social development projects in Africa to more than $150 million.

The Financial Times, one of the world's leading business news organisations, is recognised internationally for its authority, integrity and accuracy. Providing extensive news, comment and analysis, the newspaper is printed at 23 print sites across the globe, has a daily circulation of 412,854 (ABC figures, October, 2009) and a readership of 1.3 million people worldwide in print and online.

The FT ran a special malaria supplement around World Malaria Day 2009 which can be viewed at http://www.ft.com/reports/combating-malaria-2009

One of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information, please visit www.gsk.com

GlaxoSmithKline Biologicals (GSK Biologicals), GlaxoSmithKline’s vaccines business, is one of the world’s leading vaccine companies and a leader in innovation. The company is active in vaccine research, development and production with over 30 vaccines approved for marketing and 20 more in development - both in the prophylactic and therapeutic fields. Headquartered in Belgium, GSK Biologicals has 15 manufacturing sites strategically positioned around the globe. In 2009, GSK Biologicals distributed 1.4 billion doses of vaccines – of which 130 million H1N1 vaccine doses - to 182 countries in both the developed and the developing world.Through its accomplished and dedicated workforce, GSK Biologicals applies its expertise to the discovery of innovative vaccines that contribute to the health and well-being of people of all generations around the world.

Download Factsheet - GSK's Commitment to Fighting Malaria (PDF)
Download Factsheet - RTS,S Malaria Vaccine Candidate (PDF)

Syngenta is one of the world's leading companies with more than 24,000 employees in 91 countries. As a global supplier of public health insecticides under the ICON and ACTELLIC brands, we work closely with different partners to ensure that high quality and effective products for malaria prevention are available and supported by training in their safe and effective use. Syngenta's insecticide range leads the field in indoor residual spraying (IRS) - ICON 10CS - and long-lasting insecticide treatments for mosquito nets - ICON MAXX.

In addition to our existing vector control portfolio, Syngenta is also introducing new products to combat the threat of insecticide resistance. Working with the support of IVCC, Syngenta has been developing an improved non-pyrethroid insecticide formulation designed for extended residual performance for use in IRS programs.

Vestergaard Frandsen is a leading innovator, manufacturer and exporter of complex emergency response and disease control textiles. It is guided by a unique Humanitarian Entrepreneurship business model, whose "profit for a purpose" approach has turned humanitarian responsibility into its core business.

Vestergaard Frandsen's PermaNet® is the world's best selling long-lasting insecticidal bed net, created to prevent the transmission of malaria. PermaNet® was first introduced in 2000, and an improved version called PermaNet® 2.0 was launched in 2003.

In December of 2008 Vestergaard Frandsen received World Health Organization interim recommendation for PermaNet® 3.0, the first bed net effective against insecticide resistant mosquitoes.

Vestergaard Frandsen will manufacture its 175 millionth PermaNet® bed net on World Malaria Day, April 25, 2009.

For more information about these products and about Vestergaard Frandsen, please visit our website www.vestergaard-frandsen.com